WallStreetZenWallStreetZen

NASDAQ: UTHR
United Therapeutics Corp Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
United Therapeutics earnings were $1.2B for the trailing 12 months ending Jun 30, 2025, with 19.9% growth year over year. The latest UTHR earnings report on Jun 30, 2025 announced Q2 2025 earnings of $309.5M, down 3.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, UTHR reported annual earnings of $1.2B, with 21.4% growth.

UTHR past earnings growth

How has UTHR's earnings growth performed historically?

Company
19.88%
Industry
31.56%
Market
30.48%
UTHR's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
UTHR's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
UTHR's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

UTHR earnings history

Current Revenue
$3.1B
Current Earnings
$1.2B
Current Profit Margin
40.4%
UTHR's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

UTHR Return on Equity

Current Company
18.7%
Current Industry
-9%
Current Market
27%
UTHR's Return on Equity (18.7%)... subscribe to Premium to read more.
High Return on Equity Performance

UTHR undefined

Current Company
16.5%
Current Industry
0.3%
UTHR is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when UTHR announces earnings.

UTHR undefined

Current Company
22.33%
Current Industry
8.2%
UTHR has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

UTHR vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
UTHR$1.73B$1.24B+23.11%$27.68
GMAB$1.82B$1.25B+9.89%$1.97
ASND-$194.68M-$388.26MN/A-$6.65
INCY$1.36B$870.87M+30.16%$4.42
BMRN$934.37M$657.24M+37.89%$3.44
View Top Biotech Stocks

United Therapeutics Earnings Reports & History FAQ

What were United Therapeutics's earnings last quarter?

On UTHR's earnings call on Invalid Date, United Therapeutics (NASDAQ: UTHR) reported Q2 2025 earnings per share (EPS) of $6.86, up 9.58% year over year. Total UTHR earnings for the quarter were $309.50 million. In the same quarter last year, United Therapeutics's earnings per share (EPS) was $6.26.

If you're new to stock investing, here's how to buy United Therapeutics stock.

Is United Therapeutics profitable or losing money?

As of the last United Therapeutics earnings report, United Therapeutics is currently profitable. United Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $1.24 billion, a 16.15% increase year over year.

What was UTHR's earnings growth in the past year?

As of United Therapeutics's earnings date in Invalid Date, United Therapeutics's earnings has grown 19.88% year over year. This is 11.68 percentage points lower than the US Biotechnology industry earnings growth rate of 31.56%. UTHR earnings in the past year totalled $1.24 billion.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.